The estimated Net Worth of Jorge Di Martino is at least $1.38 million dollars as of 4 January 2024. Mr Martino owns over 12,009 units of Kronos Bio stock worth over $302,605 and over the last 4 years he sold KRON stock worth over $310,181. In addition, he makes $765,105 as Chief Medical Officer & Exec. VP of Clinical Devel. at Kronos Bio.
Mr has made over 6 trades of the Kronos Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 12,009 units of KRON stock worth $14,171 on 4 January 2024.
The largest trade he's ever made was selling 18,657 units of Kronos Bio stock on 12 December 2022 worth over $33,769. On average, Mr trades about 8,541 units every 75 days since 2020. As of 4 January 2024 he still owns at least 315,246 units of Kronos Bio stock.
You can see the complete history of Mr Martino stock trades at the bottom of the page.
Jorge F. DiMartino M.D., Ph.D. is the Chief Medical Officer & Exec. VP of Clinical Devel. at Kronos Bio.
As the Chief Medical Officer & Exec. VP of Clinical Devel. of Kronos Bio, the total compensation of Mr D at Kronos Bio is $765,105. There are no executives at Kronos Bio getting paid more.
Mr D is 58, he's been the Chief Medical Officer & Exec. VP of Clinical Devel. of Kronos Bio since . There are 4 older and 6 younger executives at Kronos Bio. The oldest executive at Kronos Bio, Inc. is Dr. Norbert W. Bischofberger Ph.D., 65, who is the Pres, CEO & Director.
Jorge's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger et Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio executives and other stock owners filed with the SEC include: